A Class Action Lawsuit Notification for MoonLake Immunotherapeutics
Investors of MoonLake Immunotherapeutics, identified by the stock ticker MLTX, are being alerted to a class action securities lawsuit filed by the esteemed law firm, Levi & Korsinsky, LLP. The firm serves as the legal representative for investors affected by alleged securities fraud that occurred between March 10, 2024, and September 29, 2025. This lawsuit aims to recover the losses incurred by investors during this time frame.
Details of the Allegations
This class action lawsuit focuses on the accusations that the defendants made misleading statements or deliberately hid significant information regarding the company’s drug candidate, SLK. The allegations claim that key details were obscured, including:
False Claims About Drug Efficacy
1. The assertion that SLK and BIMZELX targeted the same molecular structure was a misrepresentation.
2. The implication that SLK's unique Nanobody structure would offer better clinical outcomes compared to the established monoclonal structure of BIMZELX was also unfounded.
3. Moreover, claims about SLK's ability to penetrate tissues more effectively than traditional drugs were unsubstantiated, raising questions about its clinical effectiveness.
Lack of Justification for Positive Statements
The complaint indicates that the defendants lacked legitimate grounds for making optimistic claims regarding SLK's supposed advantages over other treatments, including monoclonal antibodies. These revelations might have significant implications for investors seeking recovery for their losses.
What Investors Should Do Next
If you have suffered financial damages while holding shares in MoonLake during the relevant period, it is crucial to act swiftly. Investors must request to be appointed as lead plaintiff by the deadline of December 15, 2025. However, it's essential to know that participating as a lead plaintiff is not a prerequisite for gaining any form of compensation.
No Financial Risk for Participants
One of the most reassuring aspects of this class action claim is that it promises no upfront costs to participants. Investors identified as class members could be entitled to compensation without incurring out-of-pocket expenses. This means there is no obligation or risk associated with your participation in this legal process.
Why Levi & Korsinsky is Your Best Choice
Levi & Korsinsky has a well-established history of advocating for investors' rights, having secured hundreds of millions of dollars for their clients over the past two decades. The firm specializes in complex securities litigation and boasts a skilled team of over 70 employees dedicated to assisting shareholders. Their proven track record includes a consistent ranking in the ISS Securities Class Action Services' Top 50 Report as one of the premier securities litigation firms in the United States.
Contact Levi & Korsinsky for More Information
If you need additional information regarding your rights as an investor or wish to discuss your specific situation with a legal expert, please reach out to:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit involves allegations of securities fraud concerning MoonLake Immunotherapeutics and its drug candidate, SLK.
What are the dates relevant to the lawsuit?
Investors who suffered losses between March 10, 2024, and September 29, 2025, may be affected.
How can I participate in the lawsuit?
To participate, request to be appointed as lead plaintiff by December 15, 2025.
Are there any costs to me as an investor?
No, eligible class members may receive compensation without any out-of-pocket costs.
Who can I contact for more information?
You can contact Joseph E. Levi at Levi & Korsinsky for inquiries regarding your involvement.
